Expressing support for the designation of May 17, 2025, as "DIPG Awareness Day" to raise awareness and encourage research into cures for diffuse intrinsic pontine glioma (DIPG) and pediatric cancers in general.
This House resolution (H. Res. 419), introduced May 15, 2025, expresses support for designating May 17, 2025 as “DIPG Awareness Day.” It aims to raise public awareness of diffuse intrinsic pontine glioma (DIPG) and to encourage increased research into cures for DIPG and pediatric cancers more broadly. The resolution highlights grim DIPG statistics—including poor survival rates, high mortality from brain tumors in children, and the lack of prognosis improvement over decades—and urges greater federal funding for pediatric cancer research. It is a non-binding, symbolic measure that signals congressional intent and encourages public and private sector action, but it does not itself create new funding or binding policy. The resolution was introduced by Representative Dingell (along with several cosponsors) and referred to the Committee on Energy and Commerce. As a non-binding expression, its primary effects are to raise awareness, inform the public, and potentially influence funding priorities and philanthropic support rather than to mandate specific programs or expenditures.
Key Points
- 1Designation support: The resolution expresses support for designating May 17, 2025, as “DIPG Awareness Day” to foster awareness and advocacy.
- 2Public awareness and funding challenges: It urges the public to become more informed about DIPG and the challenges facing pediatric cancer research funding.
- 3Expanded DIPG research and care: It endorses expanded research to better understand DIPG, develop effective treatments, and provide comprehensive care for affected children and their families.
- 4Funding considerations: It encourages public and private funders to consider the mortality rate of DIPG and the life-years lost when reviewing grant applications.
- 5Context and rationale: The resolution presents DIPG statistics (incidence, poor prognosis, 5-year survival <1%, median survival ~9 months, unchanged prognosis for 40+ years) to justify increased emphasis on research and funding.